Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Consensus PT from Analysts

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned an average rating of "Buy" from the eight brokerages that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $12.67.

A number of research firms have recently issued reports on IMUX. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. StockNews.com cut shares of Immunic from a "hold" rating to a "sell" rating in a research report on Saturday, February 22nd. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $17.00 target price on shares of Immunic in a research note on Wednesday, February 26th.

Immunic Price Performance

NASDAQ:IMUX traded down $0.05 during trading hours on Monday, hitting $1.13. The stock had a trading volume of 337,013 shares, compared to its average volume of 968,788. The company has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.25. Immunic has a one year low of $0.92 and a one year high of $2.11. The firm has a market capitalization of $101.34 million, a price-to-earnings ratio of -0.91 and a beta of 1.89.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IMUX. Focus Partners Wealth grew its position in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after buying an additional 23,610 shares during the last quarter. 683 Capital Management LLC boosted its holdings in shares of Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock valued at $700,000 after acquiring an additional 15,349 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after purchasing an additional 177,542 shares during the period. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after purchasing an additional 22,200 shares during the period. Hedge funds and other institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.